Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKontoyannis, Christos-
dc.contributor.authorOrkoula, Malvina-
dc.contributor.authorKarampas, Ioannis-
dc.contributor.authorZissi, Georgia-
dc.contributor.authorSkorda, Dimitra-
dc.contributor.authorSerpi, E-
dc.contributor.otherΚοντογιάννης, Χρήστος-
dc.contributor.otherΌρκουλα, Μαλβίνα-
dc.contributor.otherΚαραμπάς, Ιωάννης-
dc.contributor.otherΖήση, Γεωργία-
dc.contributor.otherΣκορδά, Δήμητρα-
dc.contributor.otherΣέρπη, Ελευθερία- Μαΐου 2007el
dc.description.abstractPolymorphs of an Active Pharmaceutical Ingredient (API) can have different chemical and physical properties and, thus, a direct impact on the process-ability of the drug substance and the quality/performance of the drug product, such as stability, dissolution, and bioavailability. Therefore, identification of the crystal phase of an API is of outmost importance. In this work methodologies were developed based on X-ray powder diffraction and IR for the identification of the crystal phase of two APIs (Atorvastatin Calcium and Donepezil HCl) in commercial tablets.el
dc.subjectActive Pharmaceutical Ingredient (API)el
dc.subjectDonepezil HClel
dc.subjectAtorvastatin Calciumel
dc.subjectX-ray powder diffractionel
dc.subjectCrystal phaseel
dc.titleIdentification of drug polymorphs in tabletsel
dc.typeConference (paper)el
dc.typeResearch papersel
dc.subject.alternativeΔραστική φαρμακευτική ουσίαel
dc.subject.alternativeΥδροχλωρική Δονεπεζίληel
dc.subject.alternativeΠερίθλαση ακτίνων Χel
dc.subject.alternativeΦασματοσκοπία υπερύθρουel
dc.subject.alternativeΚρυσταλλική φάσηel
dcmitype.EventΠανελλήνιο Φαρμακευτικό Συνέδριο, 13οel
dcterms.locationΑθήνα, Ελλάδαel
Appears in Collections:Τμήμα Φαρμακευτικής (Δημοσ. Π.Π. σε συνέδρια)

Files in This Item:
File Description SizeFormat 
PMO030.pdf278.79 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.